CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-15). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2609 · Search date 2026-08-15 · Methodology v0.7

Catheter clamping before removal,
does it really help with Improved trial-without-catheter success and prevention of recatheterization?

30-Second Summary
D
Evidence Grade D · 34 · Safety warning
Voiding success did not improve, while short-term clamping increased UTI and delayed first void
Pooled UTI was significantly higher overall, RR 1.47, and for catheter use of seven days or less, RR 1.69. Unnecessary clamping therefore carries a meaningful infection and delayed-voiding signal. If the clamp is released late, bladder overfilling and urethral injury may also occur, although this harm was not quantified as a pooled RR.
What the
research shows
The grade is D with 34 points. In a randomized trial of 845 men with BPH-related acute urinary retention, seven-day trial-without-catheter success was 65.2% with clamping versus 68.6% with free drainage. A meta-analysis of 17 studies and 3,908 participants likewise found no bladder-function benefit and found more UTI with short-term use, RR 1.69.
What the
ads claim
Clamping physically creates cycles of bladder filling and drainage. That fact does not establish better voiding after removal; the 845-participant trial did not support the clinical claim.
*

Useful facts when choosing a product

  • Clamping periodically blocks and releases drainage to cycle bladder filling and emptying.
  • Both arms of the large trial received the same prostate medications for seven days.
  • The meta-analysis found more UTI and delayed first void with short-term clamping.
Gap Measurement · Verdict 2609 · D 34
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Both groups in the large trial received tamsulosin 0.2 mg and finasteride 5 mg for seven days; clamping was the difference. The 2023 review of 17 studies and 3,908 participants reported UTI RR 1.47 (95% CI 1.26 to 1.72), short-term RR 1.69 (1.42 to 2.02), and time-to-first-void SMD 0.19 (0.08 to 0.29), all unfavorable. Populations and estimands differ, and pivotal-trial funding could not be confirmed.

02

Why this is classified as D (34)

A large hard-outcome randomized trial was null and pooled evidence showed no benefit. Mixed populations and estimands do not establish repeated precise refutation, and no validated benefit threshold was available, giving D with 34 points.

Counterpoint. Long-term catheterization, neurogenic bladder, and procedure-specific protocols are separate questions.

Rejudgment record. Cross-check applied — Cross-checked group denominators and TWOC rates in the large RCT against the meta-analysis populations, UTI estimates, and first-void result

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI1Mixed funding sources
Effect sizeE0Null
PrecisionC0The confidence interval leaves room for benefit

The scoring table and the verdict agree (D).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Increased TWOC success in BPH-related acute urinary retentionDThe 845-participant trial found 65.2% versus 68.6%.
Prevention of urinary tract infectionDPooled UTI increased, RR 1.47.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Yuan Zhengyong, He Changxiao, Yan Shibing, Wu Caiwen. 2014Prospective randomized controlled trial405Funding not confirmed in accessible materialFirst TWOC success after seven days65.2% versus 68.6%, P>0.05; reconstructed RR about 0.95, approximate 95% CI 0.87 to 1.04Pivotal large hard-outcome trial
Ma S, Gu J, Fan X. 2023Systematic review and meta-analysis of 15 RCTs and two quasi-RCTs3,908Reported no specific grantUTI, time to first void, urinary retention, and recatheterizationUTI RR 1.47 (1.26 to 1.72); seven days or less RR 1.69 (1.42 to 2.02); time to first void SMD 0.19 (0.08 to 0.29)Synthesis of no benefit and harm across mixed populations
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-15).

Yuan Zhengyong, He Changxiao, Yan Shibing, Wu Caiwen. Randomized controlled trial on the efficacy of bladder training before removing the indwelling urinary catheter in patients with acute urinary retention associated with benign prostatic hyperplasia. Scand J Urol. 2014;48(4):400-404. PMID: 24697345. DOI: 10.3109/21681805.2014.903512.
checked
Ma S, Gu J, Fan X. Need to clamp indwelling urinary catheters before removal after different durations: a systematic review and meta-analysis. BMJ Open. 2023;13:e064075. PMID: 36792329. PMCID: PMC9933763. DOI: 10.1136/bmjopen-2022-064075.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-15 · Corrections: none

Cite this verdict

Catheter clamping before removal x voiding success and recatheterization Evidence Grade D card
[Chamgap] Catheter clamping before removal x voiding success and recatheterization — Evidence Grade D·34. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/catheter-clamping-before-removal-twoc-success/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.